Industry Newsbiopharmam and aservierrare disease
Day One Biopharmaceuticals Accepts $2.5B Acquisition
5.2
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) said this week that France-based Servier will acquire the company for $2.5 billion, tendering all shares at $21.50 apiece. The offer represents a 68% premium to the $12.78 pre-announcement close and is expected to close in the second quarter, subject to customary closing conditions and shareholder approval.
Key Points
- 1Announces acquisition: Servier to buy Day One for $2.5 billion, tendering shares at $21.50.
- 2Highlights strategic fit: Servier cites rare-cancer experience to advance Day One’s pediatric glioma program.
- 3Requires approvals: Transaction expected to close in Q2, subject to shareholder approval and closing conditions.
Scoring Rationale
Official $2.5B acquisition announcement provides credible market insight, but limited AI/ML relevance constrains portal impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
